Silverback Therapeutics
Silverback Therapeutics is a biotech company where Naomi Hunder previously worked.
Facts
- HQ
- Seattle
- Sectors
- Biotech, Biopharmaceuticals, Life Sciences
- Stage
- Series C
- Members see funding amounts. .
Is this your organization? Claim it
Alexandria Executive Chairman Joel Marcus Says Pandemic Is Shifting Biotech Toward Hubs Like Seattle as Investment Surges
Alexandria Real Estate Equities chairman Joel Marcus says the pandemic is accelerating biotech investment and changing industry geography, reinforcing hubs like Seattle where his company has extensive lab real estate, tenants, and venture investments.
SPACs Let Founders Reach Public Markets Faster and Keep Larger Equity Stakes, Say Startup Observers
The article explains how SPACs (special purpose acquisition companies) let founders and early employees reach liquidity faster and often retain larger ownership stakes than through later-stage VC or private equity rounds. Using examples like Sana Biotechnology and Seattle entrepreneur Sujal Patel, it argues SPACs can preserve founders' equity by bypassing dilutive funding rounds.
Sana Biotechnology Raises $587.5M in IPO, Debuts on Nasdaq as SANA with $6B Market Value
Sana Biotechnology raised $587.5 million by pricing 23.5 million shares at $25 in its IPO and began trading on Nasdaq under ticker SANA, with shares jumping about 40% on debut to close at $35.10. The 3-year-old Seattle gene-editing company, pre-revenue and led by former Juno executives, aims to use the proceeds to advance gene and cell therapies—including cancer treatments—and may file drug applications as early as 2022.
See all 13 stories, episodes and videos about Silverback Therapeutics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events